To see the other types of publications on this topic, follow the link: International consulting.
Journal articles on the topic 'International consulting'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'International consulting.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Wanhill, Stephen. "International Consulting Economists' Association." Project Appraisal 3, no. 2 (June 1988): 124. http://dx.doi.org/10.1080/02688867.1988.9726669.
Full text
2
Desmond, Edward, and Christopher R. Peter. "International Tuberculosis Laboratory Consulting." Clinical Microbiology Newsletter 36, no. 16 (August 2014): 123–28. http://dx.doi.org/10.1016/j.clinmicnews.2014.07.003.
Full text
3
Cooper, Signe S. "Consulting with International Visitors." Journal of Continuing Education in Nursing 19, no. 6 (November 1988): 276–77. http://dx.doi.org/10.3928/0022-0124-19881101-12.
Full text
4
Shugan, Steven M. "Editorial: Consulting, Research, and Consulting Research." Marketing Science 23, no. 2 (May 2004): 173–79. http://dx.doi.org/10.1287/mksc.1040.0078.
Full text
5
Meng, Xianbao, and Yuehua Xiong. "Analysis and Related Suggestions on the Whole Process Engineering Consulting Service Mode at Home and Abroad." Frontiers Research of Architecture and Engineering 4, no. 1 (May 19, 2021): 17. http://dx.doi.org/10.30564/frae.v4i1.2758.
Full textAbstract:
This paper first introduces the basic connotation of China’s whole process engineering consulting. Immediately, analyze the organization model, service procurement model and charging standards of foreign whole-process engineering consulting (international terminology full-life cycle engineering consultant). Second, discuss the government’s role in the development of engineering consulting from two aspects: service management and market access. Finally, combined with the above analysis, the specific problems faced in the implementation process of the whole process engineering onsulting are compared. Provide relevant suggestions on how companies and individuals respond to industry development trends.
6
Ebel, Roland. "New Opportunities in International Horticultural Consulting." HortScience 52, no. 9 (September 2017): 1140. http://dx.doi.org/10.21273/hortsci12300-17.
Full text
7
Nilsook, Prachyanun, and Panita Wannapiroon. "International Distance Consulting via Web Conferencing." International Journal of Emerging Technologies in Learning (iJET) 9, no. 4 (June 14, 2014): 60. http://dx.doi.org/10.3991/ijet.v9i4.3736.
Full text
8
Ambos, Tina C., and Bodo B. Schlegelmilch. "Managing knowledge in international consulting firms." Journal of Knowledge Management 13, no. 6 (October 23, 2009): 491–508. http://dx.doi.org/10.1108/13673270910997141.
Full text
9
Aleshnikova, V. I., and A. N. Mishchenko. "Compliance in corporate culture: codes of ethics and conduct of consultants." E-Management 4, no. 2 (July 31, 2021): 4–10. http://dx.doi.org/10.26425/2658-3445-2021-4-2-4-10.
Full textAbstract:
For a long time, the point of view on compliance as a set of initiatives aimed at preventing illegal actions dominated. Currently, an extended interpretation of compliance is becoming widespread, which should also cover the ethical aspects of doing business.During the analysis, it was found that ethical standards in consulting were formed simultaneously with the formation of the consultant profession. This allows us to draw a conclusion about the successful century-old practice of implementing ethical codes into the corporate culture of consulting firms. This article is a continuation of the authors’ research in the field of management consulting.The purpose of the study is to analyse the Russian and foreign experience of implementing ethical standards and compliance control in the field of management consulting. The methodological basis of the research is the methods of logical, comparative, expert analysis, marketing research. The informational basis of the research is regulatory legal acts, official websites and documents of consulting companies and professional associations of consultants, expert assessments and ratings of consulting firms.The article reveals an interconnected three-level system of international, national and intra-company standards of business ethics and professional practice; gives examples of reputational risks of well-known international consulting companies; justifies the role of consulting firms in the formation of the ethical structure of business. The practical significance of the study is to focus the attention of client companies on the need to familiarize themselves with the standards of ethics and business practices before concluding a contract with a consulting firm.
10
Peirano-Vejo, Maria Elisa, and Ralph E. Stablein. "Do consultants in corporate governance share a community? An empirical study on their practice." Journal of Management & Organization 16, no. 2 (May 2010): 299–313. http://dx.doi.org/10.5172/jmo.16.2.299.
Full textAbstract:
AbstractWe present an empirical study on the community of management consultants in the specialty of corporate governance. Although most studies on consulting are done on large multinational consulting firms, we suggest an alternative framework that encompasses the heterogeneity of the industry, considering also the smaller consulting firm and the independent consultant. We have qualitatively studied the practice of consultants specialized in corporate governance and looked for evidence of community belonging. Drawing on a Kuhnian theoretical framework and adapting his notion of knowledge creation to a governance consulting scenario, we explore community belonging, entry and exit mechanisms into the consulting community of governance, common culture and language, and regulation of the community. Findings confirm that consultants have mixed professional identities and an overlapping of memberships of various communities. Our results show that although no formal regulation or organization regulates corporate governance consulting, mechanisms such as reputation, career paths, experience and credibility work in strengthening the practice of the community.
11
Cooper, Stewart E. "Introduction to the special issue on international organizational consulting: Consulting psychology goes global." Consulting Psychology Journal: Practice and Research 64, no. 4 (December 2012): 243–49. http://dx.doi.org/10.1037/a0031584.
Full text
12
Lowman, Rodney L. "Frontier no more: International consulting skills as necessary minimal competencies for consulting psychologists." Consulting Psychology Journal: Practice and Research 64, no. 4 (2012): 338–43. http://dx.doi.org/10.1037/a0031676.
Full text
13
Dobrea, Răzvan Cătalin, and Mihaela Ispas. "Comparative Analysis of Consulting Services in Five European Countries." Valahian Journal of Economic Studies 8, no. 2 (October 1, 2017): 7–16. http://dx.doi.org/10.1515/vjes-2017-0013.
Full textAbstract:
Abstract The work “Comparative analysis of consulting services in five European countries” intends to offer a general picture of consulting services from five European countries (Germany, United Kingdom, Italy, Finland and Romania), through comparative analysis of the indicators presented in FEACO studies: increasing rate of turnover of the consulting market, export level, the evolution of the number of consultant, the evolution of the fees of the consultant, types of consulting services, main field where the clients that request consulting services come from. The main motivation of this research consisted of understanding the reasons for which the transformations that occurred on the consulting market are perceived differently by each of the countries that were analysed. A first step in the process of understanding the management consultancy is represented by defining it, first according to the vision of well-known authors, experienced consultants and secondly, according to the vision of profession organism on international and local level. In order to understand the way consultancy evolved in time it is necessary to present a short history with focus on the moments that led to the transformations which we have nowadays in this industry. The last part of the work was dedicated to the comparative analysis of the consultancy markets in the five countries. The novelty degree of the work is represented by the fact that all the strong points identified in the case of the four countries (Germany, United Kingdom, Italy, Finland) will constitute possible development directions for the Romanian consulting market.
14
Clarke, Mari H. "On the Road Again: International Development Consulting." NAPA Bulletin 20, no. 1 (January 8, 2008): 71–74. http://dx.doi.org/10.1525/napa.2001.20.1.71.
Full text
15
Li, Qianqian, and Qinqin Zheng. "Chinese customers' loyalty to international consulting firms." Service Industries Journal 33, no. 15-16 (December 2013): 1495–513. http://dx.doi.org/10.1080/02642069.2011.635300.
Full text
16
Chernukha, T. S., and T. S. Bunchykova. "The Strategies and Forms of Entrance to the International Market for a Consulting Company." Business Inform 5, no. 520 (2021): 48–56. http://dx.doi.org/10.32983/2222-4459-2021-5-48-56.
Full textAbstract:
The article necessitates studying the theoretical and practical aspects pertaining to the formation and choice of a strategy for the entrance of economic entities in the consulting sphere to the international market along with adaptation of certain regularities to the modification of market conditions. The article researches trends, characteristic features and tendencies of the international consulting market in the field of technical design and engineering; outlines key concepts of the industry; presents proportions of this type of business; identifies the dynamics of the market of consulting services on technical maintenance and consulting in the USA and the countries of the European Union. The factors of influence on the international policy of the consulting company for technical design and engineering are analyzed and a block scheme for the formation of an international strategy for entrance to the world market is presented. The stages of formation of the strategy and form of the consulting company’s entry into the international market are defined. The analysis of the level of involvement in various strategies for entering foreign markets allowed to systematize the strategies for entering foreign markets according to certain criteria. As a result of the research, new vectors of strategic approaches to the consulting company’s activities in the international market are allocated, the attractiveness of strategic external business activities is assessed by means of the Delphi method. Prospect for further research in this direction is a substantiation of the market expansion strategy, in which the consulting company can adapt the extant services for new markets. Further development of the era of «consulting 4.0» can lead to the replacement of traditional consulting services.
17
Medvic, Stephen K. "Professional Political Consultants: An Operational Definition." Politics 23, no. 2 (May 2003): 119–27. http://dx.doi.org/10.1111/1467-9256.00187.
Full textAbstract:
Although political consultants have increasingly been the subject of scholarly research, there is little agreement as to what a ‘political consultant’ actually is. Early research in the field, and a good deal of contemporary work as well, has provided only vague conceptualisations of the term. Recent quantitative work that attempts to examine the role and impact of consultants in elections suffers from a lack of a common operational definition. After a brief review of the way systematic empirical researchers operationalise ‘professional political consultant,’ I offer a comprehensive definition that can be used in future research on the topic. Without an agreed definition to employ, the study of political consulting will remain idiosyncratic and fragmentary. That, in turn, hampers efforts to provide normative evaluation, and comparative analysis, of the consulting phenomenon.
18
Gron, O. V., and V. O. Harkusha. "The Methods for Assessing the Efficiency of the International Marketing Strategy of a Consulting Company." Business Inform 10, no. 525 (2021): 31–37. http://dx.doi.org/10.32983/2222-4459-2021-10-31-37.
Full textAbstract:
The article is aimed at exploring the features of the international market of consulting services in the sphere of technical design and engineering, analyzing the available methods for evaluating the efficiency of the international marketing strategy of a company and identifying the most relevant methods for assessing the marketing mechanism in the consulting industry. The analysis is carried out by comparing and collating the theoretical and practical results of specific criteria and methods, taking into account the specifics of the sphere of consulting, dynamism and variability of this market, which is growing rapidly and has the potential for further modifications. Trends and characteristic features of the international market of consulting engineering services are considered. The existing methods for evaluation of efficiency of the company’s international marketing strategy are analyzed and the most optimal methods are defined depending on the market in which the company operates, its internal resource capabilities and the strength of influence of environmental factors. As a result of the research, practical methods for evaluating the efficiency of the marketing strategy of a consulting company were systematized and the most efficient tools for assessing the feasibility, profitability, expedience of a particular international marketing strategy for a consulting company were specified, as well as a comprehensive strategic planning of international marketing activities was formed taking into account the peculiarities of the sphere of consulting on the basis of which the distinguished methods work. Prospects for further research are the analysis of batch methods of factor analysis, matrix regression analysis for modeling the relationships between latent variables of the marketing strategy and a more detailed assessment of its efficiency precisely for a consulting company on the international market.
19
Dobrzynski, David, Danielle Ndi, Tiffanie Markus, Yuwei Zhu, William Schaffner, and H. Keipp Talbot. "730. Hospital Readmissions Following Laboratory-Confirmed Influenza." Open Forum Infectious Diseases 5, suppl_1 (November 2018): S262—S263. http://dx.doi.org/10.1093/ofid/ofy210.737.
Full textAbstract:
Abstract Background Further understanding of hospital readmissions after influenza illness could reduce readmissions. The aim of our study was to characterize the morbidity associated with laboratory confirmed influenza hospitalizations. Methods This was a retrospective study using data from 2006 to 2016 from the Tennessee (TN) Emerging Infections Program Influenza Surveillance Network, which prospectively identifies laboratory-confirmed influenza hospitalizations in Nashville, TN and surrounding counties. Using the TN Hospital Discharge Data System, which collects information on all hospitalizations and discharges in TN, cases were linked to subsequent hospitalizations up to 1 year. The International Classification of Diseases was used to define the primary diagnosis associated with each hospitalization. Demographic characteristics and outcomes were compared by using χ2 tests for categorical variables. Multivariable logistic regression was used to compare study outcomes. Results Of the 2,897 patients with a laboratory-confirmed influenza hospitalization, 1,364 (47%) had a hospital readmission during the subsequent year (figure). Multiple readmissions occurred in 740 patients (54%). The readmission group was older, female predominant, and had more comorbidities than patients not re-hospitalized. Acute COPD/asthma exacerbation, pneumonia, septicemia, and acute renal failure were the most common causes for readmission. Underlying cardiovascular disease (OR 1.6), lung disease (OR 1.6), kidney disease (OR 1.7), diabetes (OR 1.3), immunosuppression (OR 1.6), and liver disease (OR 2.1) were associated with increased risk of readmission (table). Conclusion An influenza hospitalization is associated with increased hospital readmissions. Approximately 47% of patients hospitalized with influenza are readmitted within 1 year. Patient comorbidities could be an important link to influenza readmissions. Disclosures W. Schaffner, Merck: Member, Data Safety Monitoring Board, Consulting fee. Pfizer: Member, Data Safety Monitoring Board, Consulting fee. Dynavax: Consultant, Consulting fee. Seqirus: Consultant, Consulting fee. SutroVax: Consultant, Consulting fee. Shionogi: Consultant, Consulting fee. H. K. Talbot, sanofi pasteur: Investigator, Research grant. Gilead: Investigator, Research grant. MedImmune: Investigator, Research grant. Vaxinnate: Safety Board, none. Seqirus: Safety Board, none.
20
Albuquerque, C., A. P. Gomides, A. B. Vargas-Santos, C. Brenol, I. Pereira, K. Bonfiglioli, M. Bertolo, et al. "AB0190 DO IT FAST! EARLY ASSESSMENT BY A RHEUMATOLOGIST INCREASES THE CHANCES OF RHEUMATOID ARTHRITIS BEING TREATED WITHIN THE “WINDOW OF OPPORTUNITY”." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1394.1–1395. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3242.
Full textAbstract:
Background:The current concept of treating rheumatoid arthritis RA patients emphasizes the importance of early diagnosis and early initiation of disease-modifying drugs (DMARD) for a better prognosis of these patients.Objectives:To evaluate the impact of rheumatologic evaluation on the diagnosis of RA patients, as well as on the initiation of DMARD and on the clinical control of disease activity of these patients under real-life conditions.Methods:The REAL study included RA patients attending eleven public hospitals, from different regions of Brazil. All subjects met the ARA (1987) or ACR/EULAR (2010) RA classification criteria. Subjects were submitted to clinical interview with physical exam and review of medical records. Specialized assessment was defined as sequentially “early”, when the rheumatologist was the 1stor 2ndconsulted physician, and sequentially “late”, when the rheumatologist was consulted after two or more other doctors. Welch’st, Mann-Whitney’s U, chi-square and Spearman’s rho tests were used to test hypotheses, at significance level of 0.05. The study was approved by local ethics committees and all participants granted informed consent.Results:1057 RA patients were assessed; 89.4% (n=945) female; 56.5% (n=597) white; mean (SD) age of 56.9 (11.5) years; mean (SD) disease duration of 173.1 (114.5) months. Median [IQR] delay from symptoms onset to RA diagnosis and to the first DMARD both equaled 12 [6, 36] months. Only 28.7% received a DMARD within 6 months of symptoms onset, and 13.1% within 3 months. Most patients (64.6%) sought a general practitioner first, but 80.7% were finally diagnosed only upon rheumatologist consultation. For 28.8%, the rheumatologist was consulted after two or more other doctors. Early specialized assessment resulted in higher chances of receiving a DMARD within 6 months (OR 2.77; 95%CI [1.93, 3.97]) and within 3 months (OR 2.57; 95%CI [1.54, 4.27]) of RA onset. Late assessment was associated with lower chances of being in remission or low disease activity upon study inclusion (OR 0.53; 95%CI [0.39, 0.72]). Patients assessed early by the rheumatologist, compared to those assessed late, showed lower (mean [SD]) HAQ scores (0.877 [0.715] vs. 1.074 [0.857]; p<0.001) and DAS28-CRP scores (3.20 [1.32] vs. 3.45 [1.48]; p=0.02), and shorter delays to RA diagnosis (26.9 [46.7] vs. 44.6 [60.1] months; p<0.001) and to use the first DMARD (32.5 [58.5] vs. 50.6 [69.9] months; p<0.001). The delay to initiate a DMARD was strongly correlated to that of diagnosing RA (rho 0.816; p < 0.001).Conclusion:Most RA patients missed the window of opportunity to early treatment. Treatment delay strongly correlated with delay in diagnosis, which critically depended on the input from the rheumatologist. Late rheumatologist assessment was associated with lower chances of early RA treatment and with worse outcomes. Failure in direct transition from primary to specialized care was a common problem that needs to be solved.Disclosure of Interests:Cleandro Albuquerque Grant/research support from: Has received personal fees and/or non-financial support from Pfizer, AbbVie, AstraZeneca, Janssen, Bristol-Myers Squibb, Roche, Novartis and UCB, Consultant of: Has received personal fees and/or non-financial support from Pfizer, AbbVie, AstraZeneca, Janssen, Bristol-Myers Squibb, Roche, Novartis and UCB, Paid instructor for: Has received personal fees and/or non-financial support from Pfizer, AbbVie, AstraZeneca, Janssen, Bristol-Myers Squibb, Roche, Novartis and UCB, Speakers bureau: Has received personal fees and/or non-financial support from Pfizer, AbbVie, AstraZeneca, Janssen, Bristol-Myers Squibb, Roche, Novartis and UCB, Ana Paula Gomides Consultant of: Abvvie, Ana Beatriz Vargas-Santos Grant/research support from: Has received supporting for international medical events from AbbVie and Janssen, Claiton Brenol: None declared, Ivanio Pereira Grant/research support from: Has received consulting fees, speaking fees and supporting for internationals congresses from Roche, Pfizer, UCB Pharma, Eli-Lilly, Abbvie and Janssen, Consultant of: Has received consulting fees, speaking fees and supporting for internationals congresses from Roche, Pfizer, UCB Pharma, Eli-Lilly, Abbvie and Janssen, Paid instructor for: Has received consulting fees, speaking fees and supporting for internationals congresses from Roche, Pfizer, UCB Pharma, Eli-Lilly, Abbvie and Janssen, Speakers bureau: Has received consulting fees, speaking fees and supporting for internationals congresses from Roche, Pfizer, UCB Pharma, Eli-Lilly, Abbvie and Janssen, Karina Bonfiglioli Consultant of: Roche, Abbvie, Pfizer, Janssen and BMS, Manoel Bertolo Grant/research support from: Has participated in clinical and/or experimental studies related to this work and sponsored by Roche; has delivered speeches at events related to this work and sponsored by AbbVie and Pfizer, Consultant of: Has participated in clinical and/or experimental studies related to this work and sponsored by Roche; has delivered speeches at events related to this work and sponsored by AbbVie and Pfizer, Paid instructor for: Has participated in clinical and/or experimental studies related to this work and sponsored by Roche; has delivered speeches at events related to this work and sponsored by AbbVie and Pfizer, Speakers bureau: Has participated in clinical and/or experimental studies related to this work and sponsored by Roche; has delivered speeches at events related to this work and sponsored by AbbVie and Pfizer, Maria Fernanda Guimarães: None declared, Maria Sauma: None declared, Paulo Louzada Jr Grant/research support from: Has received supporting for internationals congresses from Bristol-Myers Squibb, UCB and consulting fees from Pfizer, Paid instructor for: Has received supporting for internationals congresses from Bristol-Myers Squibb, UCB and consulting fees from Pfizer, Speakers bureau: Has received supporting for internationals congresses from Bristol-Myers Squibb, UCB and consulting fees from Pfizer, Rina Giorgi Grant/research support from: Has received consulting fees, speaking fees and supporting for internationals congresses from Roche, Pfizer, Bristol-Myers Squibb, UCB, Eli-Lilly, AbbVie, Abbott and EMS, Consultant of: Has received consulting fees, speaking fees and supporting for internationals congresses from Roche, Pfizer, Bristol-Myers Squibb, UCB, Eli-Lilly, AbbVie, Abbott and EMS, Paid instructor for: Has received consulting fees, speaking fees and supporting for internationals congresses from Roche, Pfizer, Bristol-Myers Squibb, UCB, Eli-Lilly, AbbVie, Abbott and EMS, Speakers bureau: Has received consulting fees, speaking fees and supporting for internationals congresses from Roche, Pfizer, Bristol-Myers Squibb, UCB, Eli-Lilly, AbbVie, Abbott and EMS, Sebastião Radominsky Grant/research support from: Has received consulting and speaking fees from Abbvie, Janssen, Pfizer, Roche and UCB, Consultant of: Has received consulting and speaking fees from Abbvie, Janssen, Pfizer, Roche and UCB, Paid instructor for: Has received consulting and speaking fees from Abbvie, Janssen, Pfizer, Roche and UCB, Speakers bureau: Has received consulting and speaking fees from Abbvie, Janssen, Pfizer, Roche and UCB, Licia Mota Grant/research support from: Has received personal or institutional support from AbbVie, Janssen, Pfizer and Roche; has delivered speeches at events related to this work and sponsored by AbbVie, Janssen, Pfizer, Roche and UCB., Speakers bureau: Has received personal or institutional support from AbbVie, Janssen, Pfizer and Roche; has delivered speeches at events related to this work and sponsored by AbbVie, Janssen, Pfizer, Roche and UCB., Geraldo Castelar-Pinheiro Grant/research support from: Has received consulting fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, Glaxosmithkline, Janssen, Pfizer, Sanofi Genzyme and Roche, Consultant of: Has received consulting fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, Glaxosmithkline, Janssen, Pfizer, Sanofi Genzyme and Roche, Speakers bureau: Has received consulting fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, Glaxosmithkline, Janssen, Pfizer, Sanofi Genzyme and Roche
21
Albuquerque, C., A. P. Gomides, A. B. Vargas-Santos, C. Brenol, I. Pereira, K. Bonfiglioli, M. Bertolo, et al. "AB0191 DECREASING DELAY TO DIAGNOSIS AND TREATMENT OF RHEUMATOID ARTHRITIS: STILL DIFFICULT TO TREAT WITHIN THE WINDOW OF OPPORTUNITY." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1395–96. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3372.
Full textAbstract:
Background:The need for early rheumatoid arthritis (RA) treatment for better outcomes is widely accepted. Is that goal being achieved in real-life settings?Objectives:To evaluate changes in the delay to RA diagnosis and treatment, and in the proportions of patients being treated early along the last decades in Brazil.Methods:This study was drawn from the REAL cohort, designed to assess RA management under real-life conditions. Patients ≥ 18 years old attending public hospitals in Brazil and meeting RA classification criteria were included. Subjects were stratified according to the year their symptoms began. Delays from symptoms onset to RA diagnosis and treatment were inquired. Early RA diagnosis and treatment was assessed using three different cut points: ≤3, ≤6 and ≤12 months of symptoms onset. Mann-Kendall’s trend test, chi-square tests, Welch’s ANOVA and Games-Howell’s post-hoc tests were used to test hypotheses, at 0.05 significance level.Results:1116 RA patients were included; 89.4% female; 56.8% white; mean (SD) age 57.1 (11.5) years. A downward trend was found in the delay to RA diagnosis (tau = -0.677, p < 0.001) and treatment (tau = -0.695, p < 0.001) from 1990 to 2015 (Figures 1 and 2). The year of symptoms onset was associated with the frequency of early treatment for all defined cut points: ≤3 months (χ2= 11.25, p = 0.001), ≤6 months (χ2= 34.84, p < 0.001), and ≤12 months (χ2= 64.79, p<0.001). The more recent the year of symptoms onset, the higher the proportions of individuals treated early (Table 1). Groups stratified according to successive periods of symptoms onset differed in the mean delay to RA treatment [F(5, 372.8) = 41.9; p < 0.001]. Patients with symptoms initiated more recently (2011-2015) had significantly lower delays compared to all other groups. Nonetheless, only 36.3% of these patients with more recent disease started treatment within 6 months of symptoms onset, and 17.2% within 3 months.Table 1.Proportions of individuals with RA receiving the first DMARD within different time intervals from symptoms onset, according to the year their symptoms began.Symptoms beginning (year)Interval from symptoms onset to first DMARDN≤ 3 months≤ 6 months≤ 12 months≤ 1990 8.5%14.9%33.3%1411991 – 1995 5.3%15.8%34.7% 951996 – 200012.3%24.7%44.5%1462001 – 200511.5%26.3%49.8%2172006 – 201017.2%38.9%61.1%2392011 – 201517.2%36.3%72.0%157Figure 1.Rheumatoid arthritis diagnostic delay according to the year of symptoms beginning, from 1990 to 2015 in BrazilFigure 2.Rheumatoid arthritis treatment delay according to the year of symptoms beginning, from 1990 to 2015 in Brazil.Conclusion:Delays to RA diagnosis and treatment have decreased, and more patients have been treated within defined windows for early RA management in the last decades in Brazil. Despite all improvements, it was still difficult to attain early RA treatment. Additional efforts are warranted in pursuit of that goal.Disclosure of Interests:Cleandro Albuquerque Grant/research support from: Has received personal fees and/or non-financial support from Pfizer, AbbVie, AstraZeneca, Janssen, Bristol-Myers Squibb, Roche, Novartis and UCB, Consultant of: Has received personal fees and/or non-financial support from Pfizer, AbbVie, AstraZeneca, Janssen, Bristol-Myers Squibb, Roche, Novartis and UCB, Paid instructor for: Has received personal fees and/or non-financial support from Pfizer, AbbVie, AstraZeneca, Janssen, Bristol-Myers Squibb, Roche, Novartis and UCB, Speakers bureau: Has received personal fees and/or non-financial support from Pfizer, AbbVie, AstraZeneca, Janssen, Bristol-Myers Squibb, Roche, Novartis and UCB, Ana Paula Gomides Consultant of: Abvvie, Ana Beatriz Vargas-Santos Grant/research support from: Has received supporting for international medical events from AbbVie and Janssen, Claiton Brenol: None declared, Ivanio Pereira Grant/research support from: Has received consulting fees, speaking fees and supporting for internationals congresses from Roche, Pfizer, UCB Pharma, Eli-Lilly, Abbvie and Janssen, Consultant of: Has received consulting fees, speaking fees and supporting for internationals congresses from Roche, Pfizer, UCB Pharma, Eli-Lilly, Abbvie and Janssen, Paid instructor for: Has received consulting fees, speaking fees and supporting for internationals congresses from Roche, Pfizer, UCB Pharma, Eli-Lilly, Abbvie and Janssen, Speakers bureau: Has received consulting fees, speaking fees and supporting for internationals congresses from Roche, Pfizer, UCB Pharma, Eli-Lilly, Abbvie and Janssen, Karina Bonfiglioli Consultant of: Roche, Abbvie, Pfizer, Janssen and BMS, Manoel Bertolo Grant/research support from: Has participated in clinical and/or experimental studies related to this work and sponsored by Roche; has delivered speeches at events related to this work and sponsored by AbbVie and Pfizer, Paid instructor for: Has participated in clinical and/or experimental studies related to this work and sponsored by Roche; has delivered speeches at events related to this work and sponsored by AbbVie and Pfizer, Speakers bureau: Has participated in clinical and/or experimental studies related to this work and sponsored by Roche; has delivered speeches at events related to this work and sponsored by AbbVie and Pfizer, Maria Fernanda Guimarães: None declared, Maria Sauma: None declared, Paulo Louzada Jr Grant/research support from: Has received supporting for internationals congresses from Bristol-Myers Squibb, UCB and consulting fees from Pfizer, Paid instructor for: Has received supporting for internationals congresses from Bristol-Myers Squibb, UCB and consulting fees from Pfizer, Speakers bureau: Has received supporting for internationals congresses from Bristol-Myers Squibb, UCB and consulting fees from Pfizer, Rina Giorgi Grant/research support from: Has received consulting fees, speaking fees and supporting for internationals congresses from Roche, Pfizer, Bristol-Myers Squibb, UCB, Eli-Lilly, AbbVie, Abbott and EMS, Consultant of: Has received consulting fees, speaking fees and supporting for internationals congresses from Roche, Pfizer, Bristol-Myers Squibb, UCB, Eli-Lilly, AbbVie, Abbott and EMS, Paid instructor for: Has received consulting fees, speaking fees and supporting for internationals congresses from Roche, Pfizer, Bristol-Myers Squibb, UCB, Eli-Lilly, AbbVie, Abbott and EMS, Speakers bureau: Has received consulting fees, speaking fees and supporting for internationals congresses from Roche, Pfizer, Bristol-Myers Squibb, UCB, Eli-Lilly, AbbVie, Abbott and EMS, Sebastião Radominsky Grant/research support from: Has received consulting and speaking fees from Abbvie, Janssen, Pfizer, Roche and UCB, Consultant of: Has received consulting and speaking fees from Abbvie, Janssen, Pfizer, Roche and UCB, Paid instructor for: Has received consulting and speaking fees from Abbvie, Janssen, Pfizer, Roche and UCB, Speakers bureau: Has received consulting and speaking fees from Abbvie, Janssen, Pfizer, Roche and UCB, Licia Mota Grant/research support from: Has received personal or institutional support from AbbVie, Janssen, Pfizer and Roche; has delivered speeches at events related to this work and sponsored by AbbVie, Janssen, Pfizer, Roche and UCB., Speakers bureau: Has received personal or institutional support from AbbVie, Janssen, Pfizer and Roche; has delivered speeches at events related to this work and sponsored by AbbVie, Janssen, Pfizer, Roche and UCB., Geraldo Castelar Grant/research support from:: Has received consulting fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, Glaxosmithkline, Janssen, Pfizer, Sanofi Genzyme and Roche, Consultant of:: Has received consulting fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, Glaxosmithkline, Janssen, Pfizer, Sanofi Genzyme and Roche, Paid instructor for:: Has received consulting fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, Glaxosmithkline, Janssen, Pfizer, Sanofi Genzyme and Roche, Speakers bureau:: Has received consulting fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, Glaxosmithkline, Janssen, Pfizer, Sanofi Genzyme and Roche
22
Campbell, Carl W. "679 Freelance Consulting in Tropical Agriculture." HortScience 35, no. 3 (June 2000): 515F—515. http://dx.doi.org/10.21273/hortsci.35.3.515f.
Full textAbstract:
During a 30-year career of research, extension, and teaching in tropical fruit production, I participated frequently in international agricultural activities in countries of Central America, South America, and the Caribbean region. In 1988, I retired from the Univ. of Florida to begin a “second career” as a freelance consultant in tropical fruit production and crop diversification, working for a variety of governmental and private organizations. This presentation contains suggestions for horticultural scientists who wish to become involved in consulting in international agriculture. First, decide the kind of work you wish to do and what your area of specialization will be. Choose work for which you have enthusiasm. Get training in basic as well as applied science. It is good to have a “day job,” at least at first, as you establish a reputation in your specialty. Become proficient in the languages of the regions where you wish to work; also carefully study the cultures. When you participate in an international project, work hard and prepare good reports of your accomplishments. As your career progresses, consider carefully whether or not you will become a full-time consultant. It is a demanding way to make a living, but it can also give much satisfaction and greater independence than one finds in many other kinds of work.
23
Lemmer, Catherine. "The International Information Consultant: A Primer on Avoiding Potholes, Perils, and Pitfalls." International Journal of Legal Information 42, no. 2 (2014): 220–40. http://dx.doi.org/10.1017/s073112650001204x.
Full textAbstract:
Consultants are retained to assist libraries in identifying, designing, and implementing solutions to a wide variety of strategic, management, operational, and human resources issues. The goal of the library-consultant relationship is to improve the operations of the organization. Although often unrecognized as such, law librarians are natural consultants. Librarians are problem solvers, and as such develop and use many of the same skills as consultants in their everyday roles in the law library.For those versatile librarians skilled in change management and interested in pursuing these challenging professional opportunities, this article discusses best practices for library consultants and provides advice on how to avoid pitfalls in the context of an international case study. Part I of the article provides an introduction to professional consulting. Part II discusses the author's case study, a six-month fellowship with the Legal Resources Centre of South Africa. Part III then concludes the article with an articulation of the skills and talents exhibited by successful consultants to enable interested readers to better understand if consulting is an opportunity matched to their professional interests and skills.
24
Bygrave, William D. "Consulting Editor's Feature." Entrepreneurship Theory and Practice 18, no. 2 (January 1994): 89. http://dx.doi.org/10.1177/104225879401800205.
Full text
25
Gerard, Gregory J., and Severin V. Grabski. "International Lumberyards, Inc.: An Information System Consulting Case." Journal of Information Systems 16, no. 2 (September 1, 2002): 117–41. http://dx.doi.org/10.2308/jis.2002.16.2.117.
Full textAbstract:
Based on issues faced by an actual company, this case focuses on the design of an appropriate information systems architecture for International Lumberyards, Inc. (ILI). The design necessitates consideration of both the business strategy and the information technology that can support that strategy, since the business strategy needs to be both informed and supported by the information system. A strategy that is not supported by the requisite infrastructure will fail. Likewise, implementing technology that is not aligned with the business strategy will result, at a minimum, in a waste of resources. In the setting described in the case, the technology (or lack thereof) resulted in very constrained processes. A new technology infrastructure, aligned with the business strategy, will allow for future growth as well as addressing the limitations of the current environment. The case description forces consideration of how the organization's multiple locations will communicate with each other, and also what type of information systems software solution should be recommended. However, prior to the long-run goal of a new infrastructure, certain short-term solutions are needed to help the organization survive. The case includes teaching notes and has been designed for flexible classroom use. Due to the complexity of the case, it is recommended as an out-of-class project for use in graduate information systems classes. However, it could be used in undergraduate classes if the instructor provides additional guidance.
26
Pringot, Jacques. "Editorial: An international consulting co-editorship in 2013." Journal of the Belgian Society of Radiology 96, no. 1 (January 1, 2013): 1. http://dx.doi.org/10.5334/jbr-btr.160.
Full text
27
Shirley, “Steve.” "F international: A unique approach to computer consulting." Telematics and Informatics 2, no. 2 (January 1985): 165–68. http://dx.doi.org/10.1016/s0736-5853(85)80010-1.
Full text
28
Dyer, Esther R. "2. International Consulting in the Era of Teleconferencing." Library Management 8, no. 2 (February 1987): 28–35. http://dx.doi.org/10.1108/eb054897.
Full text
29
Leonard, H. Skipton, Arthur M. Freedman, Cori Hill, Choon Seng Ng, Jayan Warrier, and Paulina Chu. "Consulting in international contexts: Examining and testing assumptions." Consulting Psychology Journal: Practice and Research 64, no. 4 (2012): 250–67. http://dx.doi.org/10.1037/a0031662.
Full text
30
Fulkerson, John R. "Organizational consulting in international contexts: An integrative perspective." Consulting Psychology Journal: Practice and Research 64, no. 4 (2012): 325–37. http://dx.doi.org/10.1037/a0031663.
Full text
31
Svensson, Roger. "Success Determinants when Tendering for International Consulting Projects." International Journal of the Economics of Business 8, no. 1 (February 2001): 101–22. http://dx.doi.org/10.1080/13571510151075314.
Full text
32
Pereira, I., G. Ribas, G. Castro, G. Castelar, A. B. Vargas-Santos, C. Albuquerque, A. P. Gomides, et al. "THU0333 CARDIOVASCULAR COMORBIDITIES ARE COMMON IN RHEUMATOID ARTHRITIS PATIENTS WHO PRACTICE LESS PHYSICAL ACTIVITY AND WHO HAVE WORSE FUNCTIONAL CAPACITY." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 397–98. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3387.
Full textAbstract:
Background:Patients with rheumatoid arthritis have more cardiovascular comorbidities which contributes to hospitalization and mortality.Objectives:This study aims to investigate whether there is an association between cardiovascular comorbidities in RA with subgroup of patients and clinical findings of the diseaseMethods:This study is a cross-sectional part of Rheumatoid Arthritis in Real Life (REAL), which is a multicenter prospective study conducted in Brazil, involving 13 centers specialized in the care of patients with RA. All subjects met the ARA (1987) or ACR/EULAR (2010) RA classification criteria. Subjects were submitted to clinical interview with physical exam and review of medical records. A sample of 1116 patients was selected for convenience. The association between cardiovascular comorbidities (systemic arterial hypertension (HA), diabetes mellitus (DM) type2, dyslipidemia, stroke and heart failure), the clinical characteristics and laboratory parameters of RA was evaluated through chi-square hypothesis tests, Student`s t-test, Fischer exact test, correlations test and ANOVA. Also, correction Bonferoni test was used for multiple comparisons. Differences were considered statistically significant only when p ≤ 0.05.Results:89% of the patients were female, with a mean age of 58 years. 62% of patients with RA had comorbidities, with HA the most prevalent. There were statistically significant association between cardiovascular comorbidities with age (61.71±9.69years old vs 53.03±12.10) (p <0.001), lower educational level (n=282±66.5vs 143±33,5) (p <0.001), lower physical activity (n=132±73.3 vs 48±26.7) (p <0.001), disease duration (18.5±9.75 years vs 14.4±8.61) (p <0.001), positive anti-CCP test (60.5% vs 39.5%) (p = 0.027), high clinical disease activity index CDAI) (65.9%vs 34.1%) (p <0.001), DAS28VHS (3.72±1.46 vs 3.45±1.58) (p = 0.008) and HAQ score (1.00±0.76) vs 0.83±0.77 (p <0.001).Conclusion:The frequency of cardiovascular comorbidities is high in RA patients and is associated with age, disease duration and positive anti-CCP test. It is also important to see that these comorbidities are more common in patients with lower frequency of physical activity and lower functional capacity, higher disease activity score and lower level of education. Better control of disease activity and extensive information to patients about the importance of exercise should be parallel objectives in RA.Disclosure of Interests:Ivanio Pereira Grant/research support from: Has received consulting fees, speaking fees and supporting for internationals congresses from Roche, Pfizer, UCB Pharma, Eli-Lilly, Abbvie and Janssen, Consultant of: Has received consulting fees, speaking fees and supporting for internationals congresses from Roche, Pfizer, UCB Pharma, Eli-Lilly, Abbvie and Janssen, Paid instructor for: Has received consulting fees, speaking fees and supporting for internationals congresses from Roche, Pfizer, UCB Pharma, Eli-Lilly, Abbvie and Janssen, Speakers bureau: Has received consulting fees, speaking fees and supporting for internationals congresses from Roche, Pfizer, UCB Pharma, Eli-Lilly, Abbvie and Janssen, Gabriela Ribas: None declared, G Castro: None declared, Geraldo Castelar Grant/research support from:: Has received consulting fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, Glaxosmithkline, Janssen, Pfizer, Sanofi Genzyme and Roche, Consultant of:: Has received consulting fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, Glaxosmithkline, Janssen, Pfizer, Sanofi Genzyme and Roche, Paid instructor for:: Has received consulting fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, Glaxosmithkline, Janssen, Pfizer, Sanofi Genzyme and Roche, Speakers bureau:: Has received consulting fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, Glaxosmithkline, Janssen, Pfizer, Sanofi Genzyme and Roche, Ana Beatriz Vargas-Santos Grant/research support from: Has received supporting for international medical events from AbbVie and Janssen, Cleandro Albuquerque Grant/research support from: Has received personal fees and/or non-financial support from Pfizer, AbbVie, AstraZeneca, Janssen, Bristol-Myers Squibb, Roche, Novartis and UCB, Consultant of: Has received personal fees and/or non-financial support from Pfizer, AbbVie, AstraZeneca, Janssen, Bristol-Myers Squibb, Roche, Novartis and UCB, Paid instructor for: Has received personal fees and/or non-financial support from Pfizer, AbbVie, AstraZeneca, Janssen, Bristol-Myers Squibb, Roche, Novartis and UCB, Speakers bureau: Has received personal fees and/or non-financial support from Pfizer, AbbVie, AstraZeneca, Janssen, Bristol-Myers Squibb, Roche, Novartis and UCB, Ana Paula Gomides Consultant of: Abvvie, Manoel Bertolo Grant/research support from: Has participated in clinical and/or experimental studies related to this work and sponsored by Roche; has delivered speeches at events related to this work and sponsored by AbbVie and Pfizer, Paid instructor for: Has participated in clinical and/or experimental studies related to this work and sponsored by Roche; has delivered speeches at events related to this work and sponsored by AbbVie and Pfizer, Speakers bureau: Has participated in clinical and/or experimental studies related to this work and sponsored by Roche; has delivered speeches at events related to this work and sponsored by AbbVie and Pfizer, Paulo Louzada Jr Grant/research support from: Has received supporting for internationals congresses from Bristol-Myers Squibb, UCB and consulting fees from Pfizer, Paid instructor for: Has received supporting for internationals congresses from Bristol-Myers Squibb, UCB and consulting fees from Pfizer, Speakers bureau: Has received supporting for internationals congresses from Bristol-Myers Squibb, UCB and consulting fees from Pfizer, Rina Giorgi: None declared, Maria Fernanda Guimarães: None declared, Sebastião Radominsky Grant/research support from: Has received consulting and speaking fees from Abbvie, Janssen, Pfizer, Roche and UCB, Consultant of: Has received consulting and speaking fees from Abbvie, Janssen, Pfizer, Roche and UCB, Paid instructor for: Has received consulting and speaking fees from Abbvie, Janssen, Pfizer, Roche and UCB, Speakers bureau: Has received consulting and speaking fees from Abbvie, Janssen, Pfizer, Roche and UCB, Karina Bonfiglioli Consultant of: Roche, Abbvie, Pfizer, Janssen and BMS, Maria de Fátima Sauma: None declared, Claiton Brenol: None declared, Evandro Coutinho: None declared, Licia Mota Grant/research support from: Has received personal or institutional support from AbbVie, Janssen, Pfizer and Roche; has delivered speeches at events related to this work and sponsored by AbbVie, Janssen, Pfizer, Roche and UCB., Speakers bureau: Has received personal or institutional support from AbbVie, Janssen, Pfizer and Roche; has delivered speeches at events related to this work and sponsored by AbbVie, Janssen, Pfizer, Roche and UCB.
33
Pereira, I., T. Coan, G. Castro, G. Castelar, A. B. Vargas-Santos, C. Albuquerque, A. P. Gomides, et al. "SAT0086 THE PRESENCE OF COMORBIDITIES IN PATIENTS WITH RHEUMATOID ARTHRITIS IS ASSOCIATED WITH BAD PATIENT-REPORTED OUTCOMES (PROS)." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 976.1–977. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3400.
Full textAbstract:
Background:Patients with rheumatoid arthritis have more cardiovascular comorbidities which contributes to hospitalization and mortality.Objectives:.This study aims to investigate whether there is an association between cardiovascular comorbidities in RA with subgroup of patients and clinical findings of the diseaseMethods:This study is a cross-sectional part of Rheumatoid Arthritis in Real Life (REAL), which is a multicenter prospective study conducted in Brazil, involving 13 centers specialized in the care of patients with RA. All subjects met the ARA (1987) or ACR/EULAR (2010) RA classification criteria. Subjects were submitted to clinical interview with physical exam and review of medical records. A sample of 1116 patients was selected for convenience. The association between cardiovascular comorbidities (systemic arterial hypertension (HA), diabetes mellitus (DM) type2, dyslipidemia, stroke and heart failure), the clinical characteristics and laboratory parameters of RA was evaluated through chi-square hypothesis tests, Student`s t-test, Fischer exact test, correlations test and ANOVA. Also, correction Bonferoni test was used for multiple comparisons. Differences were considered statistically significant only when p ≤ 0.05.Results:89% of the patients were female, with a mean age of 58 years. 62% of patients with RA had comorbidities, with HA the most prevalent. There were statistically significant association between cardiovascular comorbidities with age (61.71±9.69years old vs 53.03±12.10) (p <0.001), lower educational level (n=282±66.5vs 143±33,5) (p <0.001), lower physical activity (n=132±73.3 vs 48±26.7) (p <0.001), disease duration (18.5±9.75 years vs 14.4±8.61) (p <0.001), positive anti-CCP test (60.5% vs 39.5%) (p = 0.027), high clinical disease activity index CDAI) (65.9%vs 34.1%) (p <0.001), DAS28VHS (3.72±1.46 vs 3.45±1.58) (p = 0.008) and HAQ score (1.00±0.76) vs 0.83±0.77 (p <0.001).Conclusion:The frequency of cardiovascular comorbidities is high in RA patients and is associated with age, disease duration and positive anti-CCP test. It is also important to see that these comorbidities are more common in patients with lower frequency of physical activity and lower functional capacity, higher disease activity score and lower level of education. Better control of disease activity and extensive information to patients about the importance of exercise should be parallel objectives in RA.Disclosure of Interests:Ivanio Pereira Grant/research support from: Has received consulting fees, speaking fees and supporting for internationals congresses from Roche, Pfizer, UCB Pharma, Eli-Lilly, Abbvie and Janssen, Consultant of: Has received consulting fees, speaking fees and supporting for internationals congresses from Roche, Pfizer, UCB Pharma, Eli-Lilly, Abbvie and Janssen, Paid instructor for: Has received consulting fees, speaking fees and supporting for internationals congresses from Roche, Pfizer, UCB Pharma, Eli-Lilly, Abbvie and Janssen, Speakers bureau: Has received consulting fees, speaking fees and supporting for internationals congresses from Roche, Pfizer, UCB Pharma, Eli-Lilly, Abbvie and Janssen, Thayse Coan: None declared, G Castro: None declared, Geraldo Castelar Grant/research support from:: Has received consulting fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, Glaxosmithkline, Janssen, Pfizer, Sanofi Genzyme and Roche, Consultant of:: Has received consulting fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, Glaxosmithkline, Janssen, Pfizer, Sanofi Genzyme and Roche, Paid instructor for:: Has received consulting fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, Glaxosmithkline, Janssen, Pfizer, Sanofi Genzyme and Roche, Speakers bureau:: Has received consulting fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, Glaxosmithkline, Janssen, Pfizer, Sanofi Genzyme and Roche, Ana Beatriz Vargas-Santos Grant/research support from: Has received supporting for international medical events from AbbVie and Janssen, Cleandro Albuquerque Grant/research support from: Has received personal fees and/or non-financial support from Pfizer, AbbVie, AstraZeneca, Janssen, Bristol-Myers Squibb, Roche, Novartis and UCB, Consultant of: Has received personal fees and/or non-financial support from Pfizer, AbbVie, AstraZeneca, Janssen, Bristol-Myers Squibb, Roche, Novartis and UCB, Paid instructor for: Has received personal fees and/or non-financial support from Pfizer, AbbVie, AstraZeneca, Janssen, Bristol-Myers Squibb, Roche, Novartis and UCB, Speakers bureau: Has received personal fees and/or non-financial support from Pfizer, AbbVie, AstraZeneca, Janssen, Bristol-Myers Squibb, Roche, Novartis and UCB, Ana Paula Gomides Consultant of: Abvvie, Manoel Bertolo Grant/research support from: Has participated in clinical and/or experimental studies related to this work and sponsored by Roche; has delivered speeches at events related to this work and sponsored by AbbVie and Pfizer, Paid instructor for: Has participated in clinical and/or experimental studies related to this work and sponsored by Roche; has delivered speeches at events related to this work and sponsored by AbbVie and Pfizer, Speakers bureau: Has participated in clinical and/or experimental studies related to this work and sponsored by Roche; has delivered speeches at events related to this work and sponsored by AbbVie and Pfizer, Paulo Louzada Jr Grant/research support from: Has received supporting for internationals congresses from Bristol-Myers Squibb, UCB and consulting fees from Pfizer, Paid instructor for: Has received supporting for internationals congresses from Bristol-Myers Squibb, UCB and consulting fees from Pfizer, Speakers bureau: Has received supporting for internationals congresses from Bristol-Myers Squibb, UCB and consulting fees from Pfizer, Rina Giorgi: None declared, Sebastião Radominsky Grant/research support from: Has received consulting and speaking fees from Abbvie, Janssen, Pfizer, Roche and UCB, Consultant of: Has received consulting and speaking fees from Abbvie, Janssen, Pfizer, Roche and UCB, Paid instructor for: Has received consulting and speaking fees from Abbvie, Janssen, Pfizer, Roche and UCB, Speakers bureau: Has received consulting and speaking fees from Abbvie, Janssen, Pfizer, Roche and UCB, Maria Fernanda Guimarães: None declared, Karina Bonfiglioli Consultant of: Roche, Abbvie, Pfizer, Janssen and BMS, Maria de Fátima Sauma: None declared, Claiton Brenol: None declared, Evandro Coutinho: None declared, Licia Mota Grant/research support from: Has received personal or institutional support from AbbVie, Janssen, Pfizer and Roche; has delivered speeches at events related to this work and sponsored by AbbVie, Janssen, Pfizer, Roche and UCB., Speakers bureau: Has received personal or institutional support from AbbVie, Janssen, Pfizer and Roche; has delivered speeches at events related to this work and sponsored by AbbVie, Janssen, Pfizer, Roche and UCB.
34
Scriven, M. "Evaluation Consulting." American Journal of Evaluation 16, no. 1 (February 1, 1995): 47–57. http://dx.doi.org/10.1177/109821409501600105.
Full text
35
Eden, Aimee R. "Jan Riordan: An Oral History." Journal of Human Lactation 35, no. 2 (March 22, 2019): 215–18. http://dx.doi.org/10.1177/0890334419830993.
Full textAbstract:
While conducting my dissertation research on the professionalization of breastfeeding support, I identified key “founders” of lactation consulting. I focused on the people involved in the formation of the International Board Certified Lactation Consultant, as certified by the International Board of Lactation Consultant Examiners and represented by the International Lactation Consultant Association. Jan Riordan was at the top of my list. As the editor and co-author of the first text on breastfeeding and human lactation for non-physicians, Dr. Riordan shaped the professional body of knowledge for International Board Certified Lactation Consultants and others providing clinical breastfeeding support. She was a La Leche League leader and founding member of the Kansas La Leche League International Chapter, served on the first International Board of Lactation Consultant Examiners Board of Directors, and served on the first editorial review board of the Journal of Human Lactation. She was a professor of nursing at Wichita State University for 23 years. I met her at an International Lactation Consultant Association conference in San Antonio, Texas in 2010, just after she had retired from Wichita State, and I interviewed her by phone on August 10, 2010. This is from a taped interview. (AE = Aimee Eden’s initials; JR = Jan Riordan’s initials). The University of South Florida IRB approved the full study.
36
Czarniawska, Barbara. "The Uncertainties of Consulting." International Studies of Management & Organization 43, no. 3 (October 2013): 11–21. http://dx.doi.org/10.2753/imo0020-8825430301.
Full text
37
KAMINSKA, T. М. "International Business Consulting: Evolution of its Theory and Practice." ECONOMIC THEORY AND LAW 40, no. 1 (2020): 58–73. http://dx.doi.org/10.31359/2411-5584-2020-40-1-58.
Full text
38
Horberry, J., and M. Le Marchant. "The role of institutional strengthening in international environmental consulting." Public Administration and Development 11, no. 4 (July 1991): 381–99. http://dx.doi.org/10.1002/pad.4230110407.
Full text
39
Junge, Nils, and Svetlana Negroustoueva. "Bridging Divides and Creating Opportunities in International Evaluation Consulting." New Directions for Evaluation 2019, no. 164 (December 2019): 127–39. http://dx.doi.org/10.1002/ev.20388.
Full text
40
Selene Xia, Belle, and Peng Gong. "Review of business intelligence through data analysis." Benchmarking: An International Journal 21, no. 2 (April 1, 2014): 300–311. http://dx.doi.org/10.1108/bij-08-2012-0050.
Full textAbstract:
Purpose – The purpose of this paper is to explore the role of business intelligence (BI) in a consulting company. The authors propose to analyze quality through data analysis and efficiency under different business contexts. The best processes and tools in data mining are also explored. Design/methodology/approach – Management perspectives of data analysis from Florilla Consulting Company are collected using an inductive research approach. Based on a large sample of qualitative data, cost-and-benefit analysis is used to assess the BI technologies as a strategic necessity to Florilla Consulting Company. Findings – Findings classify the best processes and tools of data analysis under different business scenarios. The authors also propose a revised process and tools for Florilla Consulting Company to be further evaluated by future research. Practical implications – The insights offered in this paper derives authentic value for any consulting company that is interested to benefit from the opportunities bought by the BI technologies. Quality management also gets a new dimension when technology is integrated into business. Originality/value – This study has challenged the way quality is managed in Florilla Consulting Company. The connection of BI to quality management is explored via an empirical study of a consulting company by linking theory with practice.
41
Haslam, Simon. "Estimating the Size of National Management Consultancy Markets." Management Consulting Journal 2, no. 1 (June 1, 2019): 1–7. http://dx.doi.org/10.2478/mcj-2019-0001.
Full textAbstract:
Abstract In 2018, a research project was initiated by a team connected with the International Council for Management Consulting Institutes to analyse the factors that account for the relative strength of country’s management consulting sector. The results of this project, the Consulting Readiness Index (CRI) were reported in the previous issue of the Management Consulting Journal (Haslam et al, 2018). Since the development of the CRI, further investigation has been conducted to enable the ingredients of the CRI to estimate the financial value of national management consulting markets. This paper describes the approach, the results and the implications.
42
Pelham, Alfred. "The impact of industry and training influences on salesforce consulting time and consulting effectiveness." Journal of Business & Industrial Marketing 24, no. 8 (October 9, 2009): 575–84. http://dx.doi.org/10.1108/08858620910999448.
Full text
43
KOVALENKO, Albina, Kseniia KOVTUNENKO, and Yuliia PRODIUS. "Trends of innovative development of intermediary activities of consulting services." Economics. Finances. Law, no. 4/3 (April 30, 2020): 34–36. http://dx.doi.org/10.37634/efp.2020.4(3).7.
Full textAbstract:
Introduction. The international practice of mediation confirms the effectiveness of consulting services in solving problems of formation and development of innovative infrastructure in the economy of developed countries. Many research studies.An analysis and implementation of innovative trends requires constant th improvement and helps provide better services. The purpose of this paper is to formulate the main tendencies of innovative development of the intermediary activity of consulting services. Results. The popularity of consulting in Ukraine has been progressively relative to developed countries. The modern activity of various intermediary companies providing consulting services is aimed at qualitative innovative changes. The essence of mediation consulting services is a tool for developing partnerships that arise between the state, business, science and education, with regard to the rational use of information and intellectual resources in the enterprise innovation management system. For mediation, it is important to form a team of consultants who would possess quality information and intellectual resources and are able to turn them into professional services. Сonsulting services include: general tendency of globalization of economy, possibility of using thinking, ideas and experience of manager-consultant, adaptation of foreign experience to the conditions of national economy. Conclusion. Based on the conducted research it can be determined that the current stage of development of the intermediary activity of consulting services in Ukraine is transitional. It is innovation that promotes dynamic self-development and ensures the competitiveness of the enterprise in the market. Provided that the positive trends of innovative development for intermediary enterprises are analyzed and implemented, the country's economy will be able to occupy a worthy place in the global process of economic development.
44
Scheuer, Markus. "The international competitiveness of German consulting engineering: results of an international benchmarking study." Service Industries Journal 23, no. 1 (January 2003): 95–118. http://dx.doi.org/10.1080/02642060412331300802.
Full text
45
Nahavandi, Afsaneh, and Susan Chesteen. "The Impact of Consulting on Small Business: A Further Examination." Entrepreneurship Theory and Practice 13, no. 1 (October 1988): 29–40. http://dx.doi.org/10.1177/104225878801300104.
Full textAbstract:
The present study focuses on the impact of consulting on small businesses and identifies the reasons why small businesses do not implement some of the recommendations that they receive from consultants. A mail survey of 126 businesses that had sought assistance from the SBDC at the University of Utah was conducted. Results obtained from 106 respondents (84% response rate) indicate that overall, business manager/owners were highly satisfied with the services they received and that they found them useful. They also reported that the consulting had a positive impact on their business. Appropriateness and lack of consultant expertise were cited as primary reasons for not implementing some of the recommendations. The results are discussed in terms of areas in which the SBDCs could improve the assistance they provide small businesses and future directions for research.
46
Lauper, K., D. Mongin, S. A. Bergstra, D. Choquette, C. Codreanu, D. De Cock, L. Dreyer, et al. "OP0231 COMPARATIVE EFFECTIVENESS OF JAK-INHIBITORS, TNF-INHIBITORS, ABATACEPT AND IL-6 INHIBITORS IN AN INTERNATIONAL COLLABORATION OF REGISTERS OF RHEUMATOID ARTHRITIS PATIENTS (THE “JAK-POT” STUDY)." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 146–47. http://dx.doi.org/10.1136/annrheumdis-2020-eular.346.
Full textAbstract:
Background:In many countries, JAK-inhibitors (JAKi) have only recently been approved as treatment for patients with rheumatoid arthritis (RA).Objectives:To evaluate the effectiveness of JAKi compared to bDMARDs in RA patients in the real-world population in an international collaboration of registers (the “JAK-pot” collaboration).Methods:Patients initiating either JAKi, TNFi, IL-6i or abatacept (ABA) during a time period when JAKi were available in each country (19 registers, Table) were included. We compared the effectiveness of JAKi and bDMARDs in terms of retention using crude and adjusted survival analysis. Missing covariates were imputed using multiple imputation.Results:Among 25521 included patients, 6063 initiated a JAKi, 13879 a TNFi, 2348 ABA, and 3231 an IL-6i. Patients were on average 55 years old, with a mean disease duration 10 years, mostly seropositive (67%), female (77%) and with moderate disease activity at treatment initiation. The main reason of stopping treatment was ineffectiveness (49%), followed by adverse events (21%). Patients on JAKi were treated more often as monotherapy, had higher CRP and disease activity at baseline and had experienced more previous ts/bDMARDs. Crude median retention was 1.4 (95% CI 1.2-1.5) years for JAKi, 1.6 (1.6-1.7) for TNFi, 1.5 (1.3-1.7) for IL6i and 1.1 (1.0-1.3) for ABA. After adjustment, the hazard ratio (HR) for discontinuation tended to be lower for JAKi (HR 0.86 (0.65-1.13)) compared to TNFi, but comparable for ABA (1.02 (0.94-1.10)) and IL6i (0.99 (0.88-1.10)) (Figure 1). HRs differed notably between countries (Figure 2).Table 1.RegistersCountry, registerNJAKi, n (%)Austria, BIOREG*Belgium, TARDIS62882113 (33.6)Canada, RHUMADATA528114 (21.6)Czech Republic, ATTRA374253 (67.6)Denmark, DANBIO4721506 (10.7)Finland, ROB-FIN807234 (29.0)Germany, RABBIT*Italy, GISEA757250 (33.0)Israel, I-RECORD40094 (23.5)Netherlands, METEOR16424 (0.2)Norway, NOR-DMARD50799 (19.5)Portugal, REUMA.PT79744 (5.5)Romania, RRBR593328 (55.3)Russia, ARBITER526483 (91.8)Slovenia, BIORX.SI583146 (25.0)Spain, BIOBADASER781139 (17.8)Switzerland, SCQM2956796 (26.9)Turkey, TURKBIO2150397 (18.5)UK, BSRBR111163 (5.7)*Registers planning to participate in future studies but not included yetConclusion:The adjusted overall drug retention of JAKi tended to be higher than for TNFi, with large variation between countries. Other measures of effectiveness, such as the evaluation of CDAI remission and low disease activity are planned to shape a more comprehensive picture of JAKi effectiveness in the real world.Disclosure of Interests:Kim Lauper: None declared, Denis Mongin: None declared, Sytske Anne Bergstra: None declared, Denis Choquette Grant/research support from: Rhumadata is supported by grants from Pfizer, Amgen, Abbvie, Gylead, BMS, Novartis, Sandoz, eli Lilly,, Consultant of: Pfizer, Amgen, Abbvie, Gylead, BMS, Novartis, Sandoz, eli Lilly,, Speakers bureau: Pfizer, Amgen, Abbvie, Gylead, BMS, Novartis, Sandoz, eli Lilly,, Catalin Codreanu Consultant of: Speaker and consulting fees from AbbVie, Accord Healthcare, Alfasigma, Egis, Eli Lilly, Ewopharma, Genesis, Mylan, Novartis, Pfizer, Roche, Sandoz, UCB, Speakers bureau: Speaker and consulting fees from AbbVie, Accord Healthcare, Alfasigma, Egis, Eli Lilly, Ewopharma, Genesis, Mylan, Novartis, Pfizer, Roche, Sandoz, UCB, Diederik De Cock: None declared, Lene Dreyer: None declared, Ori Elkayam Speakers bureau: AbbVie, BMS, Pfizer, Roche, Sanofi-Aventis, Novartis, Jansen, Kimme Hyrich Grant/research support from: Pfizer, UCB, BMS, Speakers bureau: Abbvie, Florenzo Iannone Consultant of: Speaker and consulting fees from AbbVie, Eli Lilly, Novartis, Pfizer, Roche, Sanofi, UCB, MSD, Speakers bureau: Speaker and consulting fees from AbbVie, Eli Lilly, Novartis, Pfizer, Roche, Sanofi, UCB, MSD, Nevsun Inanc: None declared, Eirik kristianslund: None declared, Tore K. Kvien Grant/research support from: Received grants from Abbvie, Hospira/Pfizer, MSD and Roche (not relevant for this abstract)., Consultant of: Have received personal fees from Abbvie, Biogen, BMS, Celltrion, Eli Lily, Hospira/Pfizer, MSD, Novartis, Orion Pharma, Roche, Sandoz, UCB, Sanofi and Mylan (not relevant for this abstract)., Paid instructor for: Have received personal fees from Abbvie, Biogen, BMS, Celltrion, Eli Lily, Hospira/Pfizer, MSD, Novartis, Orion Pharma, Roche, Sandoz, UCB, Sanofi and Mylan (not relevant for this abstract)., Speakers bureau: Have received personal fees from Abbvie, Biogen, BMS, Celltrion, Eli Lily, Hospira/Pfizer, MSD, Novartis, Orion Pharma, Roche, Sandoz, UCB, Sanofi and Mylan (not relevant for this abstract)., Burkhard Leeb Grant/research support from: chairman of BioReg, Consultant of: AbbVie, Pfizer, Roche, Lilly, Grünenthal, Gebro,, Paid instructor for: Lilly, Biogen, Speakers bureau: Biogen, Lilly, Pfizer, Grünenthal, Astropharma,, Galina Lukina Speakers bureau: Novartis, Pfizer, UCB, Abbvie, Biocad, MSD, Roche, Dan Nordström Consultant of: Abbvie, Celgene, Lilly, Novartis, Pfizer, Roche and UCB., Speakers bureau: Abbvie, Celgene, Lilly, Novartis, Pfizer, Roche and UCB., Karel Pavelka Consultant of: Abbvie, MSD, BMS, Egis, Roche, UCB, Medac, Pfizer, Biogen, Speakers bureau: Abbvie, MSD, BMS, Egis, Roche, UCB, Medac, Pfizer, Biogen, Manuel Pombo-Suarez Consultant of: Janssen, Lilly, MSD and Sanofi., Speakers bureau: Janssen, Lilly, MSD and Sanofi., Ziga Rotar Consultant of: Speaker and consulting fees from Abbvie, Amgen, Biogen, Eli Lilly, Medis, MSD, Novartis, Pfizer, Roche, Sanofi., Speakers bureau: Speaker and consulting fees from Abbvie, Amgen, Biogen, Eli Lilly, Medis, MSD, Novartis, Pfizer, Roche, Sanofi., Maria Jose Santos Speakers bureau: Novartis and Pfizer, Anja Strangfeld Speakers bureau: AbbVie, BMS, Pfizer, Roche, Sanofi-Aventis, Delphine Courvoisier: None declared, Axel Finckh Grant/research support from: Pfizer: Unrestricted research grant, Eli-Lilly: Unrestricted research grant, Consultant of: Sanofi, AB2BIO, Abbvie, Pfizer, MSD, Speakers bureau: Sanofi, Pfizer, Roche, Thermo Fisher Scientific
47
Gross, Andrew C., and Jozsef Poor. "The Global Management Consulting Sector." Business Economics 43, no. 4 (October 2008): 59–68. http://dx.doi.org/10.2145/20080408.
Full text
48
Сульповар, Лев, Lev Sulpovar, Татьяна Богачева, and Tatyana Bogacheva. "Consulting Technologies as Employed by Agent Firms." Servis Plus 7, no. 4 (December 11, 2013): 25–30. http://dx.doi.org/10.12737/1693.
Full textAbstract:
The article covers the issues of agent firms'resorting to trade-mediation-oriented consulting methods and technologies. The author classifies the current consulting technologies, which are viewed as a synergy of science and art, and considers the content and specifics of such major consulting technologies as those pertaining to marketing, logistics, advertising, branding, law, finance, investment, human resources, communication, information, soft management, project management, quality management, product and service standardization and certification, security, risk management and international business.
49
Choi, Seung Uk, and Woo Jae Lee. "The Effect Of IFRS Non-Audit Consulting Services On Cost Of Debt: Evidence From Korea." Journal of Applied Business Research (JABR) 31, no. 5 (September 1, 2015): 1889. http://dx.doi.org/10.19030/jabr.v31i5.9401.
Full textAbstract:
Korean listed firms have been required to disclose their financial statements based on the International Financial Reporting Standards (IFRS) since 2011. Using pre- and post-IFRS reporting periods, we investigate the relation between IFRS non-audit consulting services provided by incumbent auditor and the cost of debt of its client for firms in the Korean Stock Market. We find evidence that IFRS non-audit consulting services are related to the decrease in cost of debt only during the post-IFRS period. In particular, receiving non-audit consulting services is positively associated with a clients bond credit rating and negatively associated with interest rate. The result generally holds when we use alternative proxies of IFRS non-audit consulting services. Finally, our results are robust to potential endogeneity issues in selecting non-audit services.
50
Worrell, Frank C. "Developing International Partnerships: American School Psychologists Consulting in Other Countries." Journal of Educational and Psychological Consultation 24, no. 4 (October 2, 2014): 261–64. http://dx.doi.org/10.1080/10474412.2014.929967.
Full text